Radiation is far from the only advisable treatment for prostate cancer scored at Gleason 3+4=7. Surgery, active surveillance in carefully selected cases, and even newer focal therapies all have a place, depending on factors like PSA level, how many biopsy cores show cancer, and whether certain aggressive growth patterns are present. A Gleason 3+4 tumor sits in the “favorable intermediate-risk” category, which makes it one of the more treatment-flexible prostate cancer diagnoses, and the real question is less about which single treatment to choose and more about which combination of factors should steer that choice.
Why 3+4 Is Not the Same As 4+3
A Gleason 7 score can be reached two ways: 3+4 or 4+3. The first number reflects the most common growth pattern, the second the next most common. When pattern 3 dominates (3+4), the tumor behaves meaningfully better than when pattern 4 dominates (4+3). In a large population-based study, men with 4+3 tumors had more than three times the risk of dying from prostate cancer compared to men with 3+4 tumors when both groups received treatment with curative intent.1PubMed Central. Differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population-based cohort A SEER-based analysis of tens of thousands of patients confirmed that 4+3 carried roughly 60% higher cancer-specific mortality than 3+4 after matching for other characteristics.2Frontiers in Oncology. Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study
The clinical gap shows up early. At diagnosis, men with 4+3 tumors tend to have higher PSA levels and a higher rate of distant metastasis than men with 3+4 tumors.3PubMed Central. Incidence of metastasis and prostate-specific antigen levels at diagnosis in Gleason 3+4 versus 4+3 prostate cancer This is why guideline bodies now split intermediate-risk prostate cancer into “favorable” and “unfavorable” subgroups rather than lumping all Gleason 7s together. Men with favorable intermediate-risk disease, which typically includes Gleason 3+4 with limited positive cores, have cancer-specific mortality rates similar to men with low-risk prostate cancer. Men with unfavorable intermediate-risk disease, including those with 4+3 or multiple adverse features, have outcomes closer to high-risk patients.4PubMed. Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations That split matters enormously when choosing treatment.
The Full Menu of Treatment Options
For a man diagnosed with Gleason 3+4 prostate cancer, the realistic treatment choices generally include radiation therapy (in several forms), surgical removal of the prostate, active surveillance in select cases, and increasingly, focal therapy. Radiation is a strong option, but framing it as the only option would ignore a large body of evidence supporting the alternatives.
Surgery, specifically radical prostatectomy, remains widely used for localized prostate cancer at this grade. A systematic review and meta-analysis of observational studies comparing surgery to radiotherapy across risk groups found that radiation was associated with roughly twice the risk of dying specifically from prostate cancer compared to surgery.5European Urology. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis That result held across subgroup analyses by risk group and radiation regimen. However, these are observational comparisons with inherent selection bias: sicker, older patients are more often steered toward radiation while healthier patients more often get surgery. No large randomized trial has definitively settled the question for intermediate-risk disease. The honest take is that both treatments offer excellent long-term cancer control for 3+4 tumors, and the choice often comes down to side-effect trade-offs and patient preference rather than a clear survival advantage for one over the other.
Can You Just Watch a 3+4 Tumor?
Active surveillance, where the cancer is monitored closely with regular PSA tests and repeat biopsies but no immediate treatment, has been well established for low-risk prostate cancer. Extending it to 3+4 tumors is more controversial, but research suggests it can be appropriate for a narrow slice of patients. A multi-institutional study of over 2,300 men with biopsy Gleason 3+4 found that roughly half had unfavorable disease at final pathology after surgery. But among men who met the strictest selection criteria, including a PSA of 10 or below, low PSA density, clinical stage T1c, and two or fewer positive biopsy cores, the rate of unfavorable disease dropped to about 19%.6Urologic Oncology: Seminars and Original Investigations. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients
More recent work has further refined who might safely defer treatment. A study using strict low-risk criteria, including PSA of 5 or below, T1 clinical stage, no evidence of tumor extending outside the prostate, and cancer involvement of 30% or less in any single biopsy core, identified a subgroup with a low predicted risk of adverse pathology, supporting consideration for surveillance or focal therapy.7Urologic Oncology: Seminars and Original Investigations. Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy The takeaway is that active surveillance is not blanket-appropriate for all 3+4 cancers, but for a carefully selected subset with very low-volume disease, it is a real option with a safety margin that many clinicians are becoming more comfortable with.
Does Radiation Alone Work, or Do You Need Hormone Therapy Too?
This is one of the sharpest practical questions for a man with Gleason 3+4. Androgen deprivation therapy (ADT), which suppresses testosterone, is commonly added to radiation for intermediate-risk prostate cancer. But whether every 3+4 patient truly needs it is debatable.
The general evidence supports a four-to-six-month course of ADT alongside radiation for intermediate-risk patients, with higher radiation doses potentially substituting for ADT in some cases.8PubMed Central. Radiotherapy and Hormone Treatment in Prostate Cancer But favorable intermediate-risk patients, the group that includes most Gleason 3+4 cancers with a single adverse feature, appear to do well with dose-escalated radiation alone. A long-term outcomes study of patients treated with high-dose intensity-modulated radiation therapy without ADT found that favorable intermediate-risk patients had PSA recurrence-free survival comparable to low-risk patients, with only about 9% experiencing biochemical failure and a single metastasis over a median of nearly six years. The authors noted this suggests a subset of intermediate-risk patients for whom radiation alone is adequate and ADT can be withheld.9PubMed Central. Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
This distinction is important because ADT carries real costs. More than half of men receiving ADT alongside radiation report some degree of bother from its side effects, most commonly hot flushes, fatigue, and sexual problems.10Practical Radiation Oncology. Decision Regret and Bother With the Addition of Androgen Deprivation Therapy to Definitive Radiation Treatment for Localized Prostate Cancer The broader side-effect profile includes decreased quality of life, cognitive changes, cardiovascular risk, bone loss, and changes in body composition.11PubMed Central. Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues Even a short course of ADT can leave a lasting mark on sexual function: at two years after treatment, men who received external beam radiation plus short-course ADT were roughly twice as likely to have shifted to worse sexual function compared to men who received radiation alone.12International Journal of Radiation Oncology*Biology*Physics. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life
A patient’s age and overall health also matter here. A study specifically examining this found that adding ADT to dose-escalated radiation improved cancer control in men under 70 with no or mild comorbidity but showed no benefit in men of any age who had moderate-to-severe other health problems.13PubMed. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer In other words, for a man who is already managing significant health issues, the side effects of ADT may outweigh any additional cancer-control benefit.
Types of Radiation and What Matters Between Them
When people say “radiation” for prostate cancer, they could mean several different things. External beam radiation therapy (EBRT) delivered as intensity-modulated radiation therapy is the most common form. Stereotactic body radiation therapy (SBRT) delivers fewer but larger doses over about a week instead of the five-to-nine weeks of conventional EBRT. Brachytherapy involves placing radioactive sources directly inside the prostate, either as permanent seeds (low-dose-rate) or temporary high-dose-rate implants.
High-dose-rate brachytherapy used as a standalone treatment has shown PSA-free survival rates ranging from 79% to 100% across published series, with local control rates above 97% and relatively low toxicity.14Brachytherapy. High-dose-rate brachytherapy as monotherapy for prostate cancer: A review A recent comparison between SBRT and high-dose-rate brachytherapy for intermediate-risk prostate cancer found that SBRT had lower biochemical failure at both five years (about 3% versus 8%) and ten years (about 10% versus 38%).15PubMed Central. SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer That is a striking gap at ten years and will likely influence treatment discussions, though longer follow-up from multiple centers is still accumulating.
One of the advances making radiation more tolerable is the use of hydrogel spacers placed between the prostate and the rectum before treatment. These create roughly a centimeter of additional separation, meaningfully reducing the radiation dose the rectal wall receives. A pooled analysis found a roughly 77% reduction in significant late rectal side effects with spacer use.16PubMed Central. Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer In phase 3 data, long-term rectal toxicity essentially disappeared in the spacer group.17Urology. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data When SBRT was delivered with a hydrogel spacer in place, one study reported no rectal toxicity beyond the first month after treatment, and no severe urinary or bowel side effects at all.18PubMed Central. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes
Side Effects of Surgery Versus Radiation
The side-effect trade-off between surgery and radiation is real and well-characterized. A nationwide register study comparing outcomes one year after treatment found that surgery led to incontinence in about 13% of men compared to 6% after radiation. On the other hand, urgency to defecate was reported by about 34% of men after radiation versus 14% after surgery. Erectile dysfunction rates were similar: 73% after surgery and 77% after radiation.19European Urology Oncology. Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study
At three years, a prospective study found surgery was associated with worse sexual function and urinary incontinence compared to external beam radiation, though surgery patients reported fewer urinary irritative symptoms than men on active surveillance.20JAMA. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years When brachytherapy was compared to surgery at five years, men treated with brachytherapy scored better in urinary and sexual domains and reported higher satisfaction.21PubMed. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial
The pattern is consistent: surgery tends to carry more urinary leakage and worse early sexual function, while radiation tends to produce more bowel irritation. Neither is side-effect-free, and which trade-off a man is more willing to live with is deeply personal. A 55-year-old man prioritizing sexual recovery may weigh the evidence differently than a 70-year-old man who already has bowel sensitivity.
Genomic Tests Can Sharpen the Decision
One of the newer tools reshaping treatment decisions is the genomic classifier, most prominently the Decipher test. This uses a panel of genes measured from biopsy or surgical tissue to estimate how aggressive a tumor is at the molecular level, independent of what it looks like under the microscope. The Decipher classifier has shown clinical utility across risk groups, helping to identify intermediate-risk patients who may safely skip ADT and those who need more aggressive treatment.22PubMed Central. The Clinical Impact of the Decipher Genomic Classifier in Prostate Cancer
In a randomized trial context, genomic classifier scores separated intermediate-risk patients into starkly different outcomes. Patients with low genomic risk had a ten-year distant metastasis rate of about 4%, while those with high genomic risk had a rate of about 16%. The benefit of dose escalation also differed: patients with higher genomic scores saw a large improvement in metastasis-free survival with higher radiation doses, while patients with lower scores saw little difference between dose levels.23International Journal of Radiation Oncology*Biology*Physics. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial For a man with Gleason 3+4 and a low Decipher score, this kind of data can provide reassurance that less aggressive treatment, possibly radiation alone without ADT, or even active surveillance, is a reasonable path.
Another pathologic feature worth knowing about is cribriform morphology, a specific growth pattern within the pattern 4 component. Among men with Gleason 3+4, the presence of cribriform architecture was an independent risk factor for cancer recurrence after surgery, with roughly a fourfold increase in the odds of biochemical recurrence.24PubMed. Cribriform Morphology in Gleason Score 3+4 Moderate-Risk Prostate Cancer: Is it Risk Factor for Biochemical Recurrence? Larger cribriform patterns were also associated with higher Decipher genomic risk scores and a substantially elevated risk of recurrence.25PubMed Central. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer If your pathology report mentions cribriform pattern, it is worth raising with your treatment team as a factor that may push the decision toward more aggressive therapy.
Focal Therapy As an Emerging Option
Focal therapy aims to destroy only the tumor within the prostate rather than treating or removing the entire gland. Techniques include high-intensity focused ultrasound (HIFU), cryotherapy, and irreversible electroporation (IRE). These approaches are most established for low-risk cancers, but evidence is building for selected Gleason 3+4 tumors.
A comprehensive review of focal therapy outcomes in grade group 3 patients (equivalent to Gleason 4+3, though many series mix 3+4 and 4+3 under “Gleason 7”) reported five-year failure-free survival in the range of roughly 60% to 88% for HIFU, depending on the study and exact tumor grade, with overall survival above 96% in one cohort followed for eight years. Focal cryotherapy for intermediate-risk patients showed three-year failure-free survival above 90%. IRE outcomes were similarly encouraging, with metastasis-free survival above 99% and cancer-specific survival of 100% at five years for the treated cohort.26PubMed Central. Focal Therapy in Grade Group 3 Prostate Cancer
The trade-off is that focal therapy often requires retreatment more frequently than whole-gland options, and long-term data beyond ten years remains thin. But for a man with a small, well-localized Gleason 3+4 tumor who prioritizes preserving urinary and sexual function, focal therapy is increasingly a legitimate conversation to have with a specialist, not a fringe option.
What Happens If the Cancer Comes Back After Radiation
One consideration that sometimes pushes men toward surgery first is the question of salvage options. If cancer recurs after surgery, radiation can be added relatively straightforwardly. If cancer recurs after radiation, the salvage path is historically more complex. But the landscape of salvage options after radiation failure has improved considerably.
A systematic review and meta-analysis of local salvage therapies after radiotherapy found that five-year recurrence-free survival ranged from about 50% after cryotherapy to about 60% after high-dose-rate brachytherapy and SBRT, with no significant difference compared to salvage surgery. Importantly, severe urinary side effects were substantially lower with all radiotherapy-based salvage approaches compared to salvage surgery: roughly 5% to 10% versus 20%.27European Urology. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) A prospective study of salvage reirradiation with external beam radiation for locally recurrent cancer after prior radiation showed a five-year biochemical recurrence-free survival of 58%, metastasis-free survival of 82%, and overall survival of 87%, with only 5% experiencing lasting severe toxicity.28PubMed Central. Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up
This means the old concern that “if radiation fails, you’re out of options” is outdated. Salvage treatments after radiation are feasible, effective, and carry tolerable side effects. That said, avoiding recurrence in the first place is preferable, and the choice of initial treatment should be made with the full picture of cancer characteristics, patient health, and quality-of-life priorities in mind rather than driven by fear of a particular failure scenario.
Cribriform Pattern and Other Pathology Details That Shift the Calculation
Not all Gleason 3+4 tumors are created equal at the microscopic level. Beyond the Gleason score itself, pathologists note features like the percentage of pattern 4, whether cribriform glands are present, and whether there is perineural invasion. These details can separate patients who are safely managed with less aggressive treatment from those who benefit from intensification.
As discussed in the genomic testing section, cribriform morphology stands out as a feature that upgrades the risk of a 3+4 tumor. A man whose biopsy shows Gleason 3+4 with a small amount of pattern 4, no cribriform growth, and a low genomic risk score is in a very different situation from a man whose biopsy shows Gleason 3+4 with extensive cribriform pattern 4 and a high Decipher score. Both have the same Gleason score on paper, but their treatment discussions should look quite different. The first might reasonably consider active surveillance or radiation alone; the second might warrant radiation plus ADT or surgery with a plan for close monitoring afterward.
This heterogeneity within the 3+4 category is exactly why the answer to “is only radiation advisable?” cannot be a simple yes or no. The Gleason score is the starting point of the conversation, not the end of it. The percentage of biopsy cores involved, PSA level and density, MRI findings, genomic test results, and specific pathologic features all feed into a decision that should be individualized. The best treatment for a given man with Gleason 3+4 is the one that accounts for all of these inputs, not the one that follows a single-pathway algorithm based on the Gleason score alone.